A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Two Doses of an Influenza A/H7N9 Vaccine Administered With or Without MF59 Adjuvant
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Influenza virus vaccine (Primary) ; Influenza A virus H7N9 vaccines; MF 59
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 05 Oct 2017 Planned initiation date changed from 12 Oct 2017 to 26 Oct 2017.
- 28 Sep 2017 Planned initiation date changed from 21 Sep 2017 to 12 Oct 2017.
- 07 Sep 2017 Planned initiation date changed from 31 Aug 2017 to 21 Sep 2017.